CD274 and neoplasm: In the KEYNOTE 12 study, involving a cohort of 132 patients with recurrence or metastasis treated with the anti-PD-1 immunotherapeutic drug pembrolizumab, 200 mg every three weeks, a greater survival was observed in patients that expressed PD-L1 in the tumor microenvironment.